Currently, Atyr Pharma Inc [ATYR] is trading at $0.68, down -3.68%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ATYR shares have lost -6.59% over the last week, with a monthly amount drifted -34.45%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Atyr Pharma Inc [NASDAQ: ATYR] stock has seen the most recent analyst activity on September 16, 2025, when RBC Capital Mkts downgraded its rating to a Sector Perform but kept the price target unchanged to $1.50 for it. Previously, Wells Fargo downgraded its rating to Equal Weight on September 15, 2025, and kept the price target unchanged to $1. On September 15, 2025, downgrade downgraded it’s rating to Market Perform but maintained its price target of $1 on the stock. H.C. Wainwright downgraded its rating to a Neutral. Cantor Fitzgerald downgraded its rating to a Neutral. Leerink Partners started tracking with a Outperform rating for this stock on February 18, 2025, and assigned it a price target of $16. In a note dated January 06, 2025, Cantor Fitzgerald initiated an Overweight rating.
This stock has fluctuated between a low of $0.68 and a high of $7.29 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $5.13 within the next 12 months. Atyr Pharma Inc [NASDAQ: ATYR] shares were valued at $0.68 at the most recent close of the market. An investor can expect a potential return of 654.41% based on the average ATYR price forecast.
Analyzing the ATYR fundamentals
Gross Profit Margin for this corporation currently stands at -4.97% with Operating Profit Margin at -413.95%, Pretax Profit Margin comes in at -395.39%, and Net Profit Margin reading is -395.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -1.0 and Total Capital is -0.86. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6540 points at the first support level, and at 0.6327 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7082, and for the 2nd resistance point, it is at 0.7411.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Atyr Pharma Inc [NASDAQ:ATYR] is 5.93. Also, the Quick Ratio is 5.93, while the Cash Ratio stands at 0.39. Considering the valuation of this stock, the price to sales ratio is 348.22, the price to book ratio is 0.82.
Transactions by insiders
Recent insider trading involved SCHIMMEL PAUL, Director, that happened on Oct 08 ’25 when 0.68 million shares were purchased. Director, SCHIMMEL PAUL completed a deal on Oct 09 ’25 to buy 0.32 million shares. Meanwhile, Director Gross Jane A bought 3750.0 shares on Mar 17 ’25.
